Literature DB >> 25522128

Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia.

Gaku Oshikawa1, Kazuhiko Kakihana2, Makoto Saito3, Jun Aoki1, Yuho Najima1, Takeshi Kobayashi1, Noriko Doki1, Hisashi Sakamaki1, Kazuteru Ohashi1.   

Abstract

Entities:  

Keywords:  acute myeloid leukaemia; allogeneic haematopoietic stem cell transplantation; azacitidine; gemtuzumab ozogamicin; maintenance therapy

Mesh：

Substances：

Year:  2014        PMID： 25522128     DOI： 10.1111/bjh.13248

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  20 in total

Review 1.  Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation?

Authors:  Marie Robin; Pierre Fenaux
Journal:  Leukemia       Date:  2020-07-13       Impact factor: 11.528

Review 2.  Hypomethylating agents after allogeneic blood stem cell transplantation.

Authors:  Thomas Schroeder; Christina Rautenberg; Rainer Haas; Guido Kobbe
Journal:  Stem Cell Investig       Date:  2016-11-28

Review 3.  Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.

Authors:  Thomas Schroeder; Christina Rautenberg; Rainer Haas; Ulrich Germing; Guido Kobbe
Journal:  Int J Hematol       Date:  2017-11-15       Impact factor: 2.490

Review 4.  Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials.

Authors:  Armin Rashidi; Roland B Walter; Martin S Tallman; Frederick R Appelbaum; John F DiPersio
Journal:  Blood       Date:  2016-06-27       Impact factor: 22.113

Review 5.  Life after transplant: are we becoming high maintenance in AML?

Authors:  A M Brunner; A T Fathi; Y B Chen
Journal:  Bone Marrow Transplant       Date:  2016-06-20       Impact factor: 5.483

Review 6.  Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation.

Authors:  Robert J Soiffer; Yi-Bin Chen
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 7.  Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation.

Authors:  Robert J Soiffer; Yi-Bin Chen
Journal:  Blood Adv       Date:  2017-11-28

Review 8.  60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy.

Authors:  Nicoletta Cieri; Katie Maurer; Catherine J Wu
Journal:  Cancer Res       Date:  2021-06-09       Impact factor: 12.701

Review 9.  Therapeutic Use of Valproic Acid and All-Trans Retinoic Acid in Acute Myeloid Leukemia-Literature Review and Discussion of Possible Use in Relapse after Allogeneic Stem Cell Transplantation.

Authors:  Øystein Bruserud; Galina Tsykunova; Maria Hernandez-Valladares; Hakon Reikvam; Tor Henrik Anderson Tvedt
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-02

10.  Allogenic Stem Cell Transplantation Abrogates Negative Impact on Outcome of AML Patients with KMT2A Partial Tandem Duplication.

Authors:  Gabriel Antherieu; Audrey Bidet; Sarah Huet; Sandrine Hayette; Marina Migeon; Lisa Boureau; Pierre Sujobert; Xavier Thomas; Hervé Ghesquières; Arnaud Pigneux; Mael Heiblig
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.